Trial Number


Age range

2 years to 21 years


Male or Female

Enrolling Patients


There remains a significant unmet medical need for more effective treatment options for pediatric subjects with solid tumors. Overall solid tumors make up to 30% of all cancers in children. Approximately 80% of these tumors are cured with conventional approaches. This is a multicenter, open-label, Phase 1/2 study of lenvatinib in combination with everolimus in pediatric subjects with relapsed or refractory solid tumors. This study will be performed on pediatric subjects with solid tumors, which were resistant to conventional therapy, and for whom there are no alternative therapies that might lead to cure.

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.

Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.